Neuromuscular Blockers
High-yield Verified · Oct 2026Act on the nicotinic acetylcholine receptor of the motor end plate — succinylcholine by opening it and keeping the end plate depolarized, the nondepolarizers by competing with acetylcholine for its binding site — and are reversed either by raising acetylcholine (neostigmine) or by removing the blocker (sugammadex).
Nursing view → administration, monitoring and patient teaching
Compare: Autonomic receptors compared — muscarinic, nicotinic, adrenergic and dopamine →
Drugs
Mechanism
Block nicotinic acetylcholine receptors at the neuromuscular junction. Depolarizing agents (succinylcholine) persistently activate the receptor (initial fasciculations → sustained depolarization → paralysis). Non-depolarizing agents (rocuronium, vecuronium, cisatracurium) competitively antagonize the receptor (no fasciculations; reversible). Sugammadex, a modified gamma cyclodextrin, reverses rocuronium or vecuronium by forming a complex with them.
The motor end plate and its nicotinic receptor
A nerve impulse opens voltage-gated calcium channels in the motor nerve terminal, and calcium drives the synaptic vesicles to release acetylcholine into a cleft about 50 nm wide. Acetylcholine binds the nicotinic receptors concentrated on the junctional folds; these are ligand-gated ion channels, and opening them lets sodium in, moving the membrane from about −90 mV to −45 mV — the endplate potential. That fires a muscle action potential, which travels down the T-tubules and releases calcium from the sarcoplasmic reticulum for contraction. Acetylcholinesterase in the cleft then hydrolyzes the remaining acetylcholine.
The receptor comes in two pentameric forms. Mature (junctional) receptors open briefly and turn over in about 14 days. Immature (fetal) receptors turn over in about 24 hours, appear within 24 hours of injury, and increase in sepsis, burns and upper or lower motor neuron disease; they resist nondepolarizing blockers but are sensitive to succinylcholine, and stimulating them lets potassium out of the muscle. Nicotinic receptors also sit on the nerve terminal itself, where they sense cleft acetylcholine and damp further release.
Succinylcholine: a depolarizing block in two phases
Succinylcholine acts like acetylcholine: it binds the end-plate receptors and generates an action potential, seen as fasciculations. Unlike acetylcholine it is not metabolized by acetylcholinesterase, so it stays bound and the end plate cannot repolarize — the phase I block. Paralysis comes in under a minute after an IV dose and, after a single dose, lasts about 4–6 minutes, because plasma cholinesterase in the blood hydrolyzes it — first to succinylmonocholine, then more slowly to succinic acid and choline. It spreads in order: the levator muscles of the face, the glottis, then the intercostals, diaphragm and the rest of the skeletal muscles.
With prolonged exposure — repeated doses or an infusion — the receptors desensitize and the block changes to phase II, which superficially resembles a nondepolarizing block: the response fades with successive stimuli (train-of-four), respiratory paralysis can be prolonged, and tachyphylaxis appears. An anticholinesterase is no help in phase I — neostigmine may prolong the phase I block — but may be considered to reverse a phase II block once nerve stimulation has confirmed it, given together with an anticholinergic to prevent cardiac rhythm disturbances.
Succinylcholine also stimulates autonomic ganglia and muscarinic receptors, which can change cardiac rhythm — bradycardia, especially in children and after a second dose — and it raises intraocular and intracranial pressure during the fasciculation phase.
Nondepolarizers: competition at the α subunit
Rocuronium, vecuronium and cisatracurium bind the receptor without opening it. They compete with acetylcholine for its binding site on the α subunit, and once their concentration at the junction is high enough relative to acetylcholine, transmission fails without the end plate ever being depolarized. Because the block is competitive, raising acetylcholine with a cholinesterase inhibitor such as neostigmine antagonizes it.
There are two structural families: the aminosteroids (rocuronium, vecuronium, pancuronium) and the benzylisoquinoliniums (cisatracurium, atracurium, mivacurium). The family predicts elimination and reversal: the aminosteroids depend on the liver (rocuronium is eliminated primarily by the liver) and include rocuronium and vecuronium, the two blockers sugammadex is used to reverse, while cisatracurium breaks down mostly by organ-independent Hofmann elimination, and benzylisoquinoliniums can release histamine (bronchospasm, hypotension, tachycardia).
Many things deepen a nondepolarizing block: inhaled anesthetics (desflurane, sevoflurane, isoflurane), aminoglycosides and clindamycin, magnesium, and calcium channel blockers, lithium and antiarrhythmics such as procainamide and quinidine — as do hypothermia, hypokalemia, hypermagnesemia and acid–base disturbances.
Two ways to reverse a nondepolarizing block
Neostigmine inhibits acetylcholinesterase, so acetylcholine accumulates and outcompetes the blocker at the nicotinic receptor. The extra acetylcholine also reaches muscarinic receptors — bradycardia, secretions, bronchoconstriction, gut motility — and neostigmine has direct postsynaptic cholinomimetic effects too, so atropine or glycopyrrolate is given before or with it. Neostigmine works best after some spontaneous recovery; given when recovery is already nearly complete it can paradoxically cause anticholinesterase-associated muscle weakness, and given without enough spontaneous recovery the lasting blocker can bring weakness back in the recovery unit (“recurarization”).
Sugammadex works on the drug instead of the synapse. It is a modified gamma cyclodextrin that forms a complex with rocuronium or vecuronium, which reduces the amount free to bind the nicotinic receptors; it can reverse moderate and deep blocks. It has no muscarinic effects of its own, but it reverses only rocuronium and vecuronium — not succinylcholine or the benzylisoquinoliniums — and anything that displaces the blocker from the complex can bring the block back.
Comparing the drugs
Mechanism, timing and reversal
| Drug | Mechanism | Structural class | Onset and duration | Reversal |
|---|---|---|---|---|
| Succinylcholine | Depolarizing agonist (phase I → phase II) | — | Onset under 1 min; a single dose lasts about 4–6 min | Not reversed by sugammadex; neostigmine may prolong phase I |
| Rocuronium | Competitive (nondepolarizing) | Aminosteroid | Rapid to intermediate onset (dose-dependent); intermediate duration | Neostigmine with an antimuscarinic, or sugammadex |
| Vecuronium | Competitive (nondepolarizing) | Aminosteroid | Clinical duration about 25–40 min under balanced anesthesia | Neostigmine with an antimuscarinic, or sugammadex |
| Cisatracurium | Competitive (nondepolarizing) | Benzylisoquinolinium | Intermediate onset and duration; not recommended for rapid-sequence intubation | Neostigmine with an antimuscarinic; not sugammadex |
| Sugammadex | Encapsulates rocuronium and vecuronium | Modified gamma cyclodextrin | — | It is the reversal agent |
— = not described in the listed sources.
How each drug is cleared
| Drug | Main route | Half-life | What changes it |
|---|---|---|---|
| Succinylcholine | Plasma cholinesterase hydrolysis; about 10% unchanged in urine | About 3–5 min | Atypical or reduced plasma cholinesterase prolongs paralysis |
| Rocuronium | Primarily the liver | About 1.4 h | Cirrhosis roughly doubles the plasma half-life |
| Vecuronium | Liver and bile; 3–35% recovered in urine within 24 h | About 65–75 min | Active 3-desacetyl metabolite (half or more of the potency) |
| Cisatracurium | Hofmann elimination (about 80%), a pH- and temperature-dependent chemical process | About 22 min | Laudanosine and other metabolites rise in renal or hepatic impairment |
| Sugammadex | Excreted unchanged by the kidney; not metabolized | About 2 h | 4, 6 and 19 h in mild, moderate and severe renal impairment |
Pharmacokinetics
- Plasma cholinesterase — succinylcholine
- Hydrolyzed in plasma to succinylmonocholine (clinically insignificant blocking activity) and then to succinic acid and choline; levels fall below detection within about 2.5 minutes of a bolus. Plasma cholinesterase falls in pregnancy, severe liver or kidney disease, burns, malignancy and infection, and with oral contraceptives, glucocorticoids, some MAO inhibitors and irreversible inhibitors such as organophosphates and echothiophate — each prolonging the block.
- Atypical plasma cholinesterase — succinylcholine
- About 1 in 2,500 patients is homozygous for the atypical plasma cholinesterase gene and is extremely sensitive to succinylcholine, with apnea or prolonged paralysis that is treated with controlled respiration. The dibucaine number — the percentage inhibition of enzyme activity by dibucaine — helps diagnose the deficiency.
- Hepatic elimination — rocuronium, vecuronium
- Rocuronium is eliminated primarily by the liver, with an elimination half-life of about 1.4 hours; in cirrhosis a larger volume of distribution about doubles its plasma half-life. Vecuronium is partly recovered in urine and in bile, and its 3-desacetyl metabolite has half or more of its potency. Both are excreted through the hepatobiliary system, so they are avoided in liver failure when an alternative is available.
- Hofmann elimination — cisatracurium
- About 80% of its clearance is spontaneous, pH- and temperature-dependent Hofmann degradation, independent of the liver and kidney; its half-life is about 22 minutes and its recovery profile is unchanged in renal impairment. The kidney and liver clear its metabolites, so laudanosine — which caused seizures in animals — builds up in renal or hepatic impairment during extended use.
- Renal excretion — sugammadex
- Not metabolized; more than 90% of a dose is excreted within 24 hours, almost all of it unchanged in urine. Its half-life of about 2 hours lengthens to 4, 6 and 19 hours in mild, moderate and severe renal impairment, and it is not recommended in severe renal impairment or dialysis.
- Ionization
- Both kinds of blocker are ionized and water-soluble (the nondepolarizers are quaternary ammonium compounds): they are poorly absorbed orally, are given IV, and do not cross the placenta in clinically relevant amounts.
Pharmacogenomics
Uses & drug choice
- Facilitation of endotracheal intubation (succinylcholine/rocuronium for rapid-sequence)
- Skeletal muscle relaxation during surgery
- Paralysis to facilitate mechanical ventilation (e.g., severe ARDS) in the ICU
- Sugammadex for reversal of rocuronium- or vecuronium-induced neuromuscular blockade in adults and children undergoing surgery
Adverse effects
- Fasciculations and postoperative myalgia (succinylcholine)
- The drug depolarizes the end plate like acetylcholine before the block sets in, so muscle fibers fire as fasciculations; muscle pain can follow.
- Apnea
- The diaphragm and intercostals are skeletal muscles with nicotinic end plates; the block spreads to them after the facial and glottic muscles, so breathing stops until the block wears off or is reversed.
- Awareness without sedation
- These drugs act only at the motor end plate and have no effect on consciousness, pain threshold or cerebration — a patient can be paralyzed but awake.
- Hyperkalemia and cardiac arrest (succinylcholine)
- Each depolarization lets potassium out of muscle; normally serum potassium rises by up to about 0.5 mEq/L. After burns, trauma, denervation or upper motor neuron injury, postjunctional receptors (including immature ones) upregulate, the risk peaking at about 7–10 days, so far more potassium is released. In an undiagnosed myopathy such as Duchenne dystrophy, rhabdomyolysis adds more.
- Malignant hyperthermia (succinylcholine)
- In susceptible muscle — often with RYR1 or CACNA1S variants — triggering agents raise myoplasmic calcium, which drives a hypermetabolic state: high oxygen demand, hypercapnia, rigidity, tachycardia and hyperthermia.
- Bradycardia (succinylcholine)
- Activation of the nicotinic receptor is accompanied by muscarinic stimulation; the effect is greater in children and after a second dose, and atropine or glycopyrrolate can mitigate it.
- Prolonged apnea (pseudocholinesterase deficiency)
- Succinylcholine is ended by plasma cholinesterase; when the enzyme is atypical or reduced, the drug is not cleared and the phase I block — and apnea — continues.
- Histamine release and hypotension
- Benzylisoquinoliniums can release histamine, causing vasodilation with hypotension, tachycardia and bronchospasm; vecuronium shows no chemically mediated histamine release at clinical doses.
- Residual weakness or recurrence of block
- A block reversed too early, a dose that outlasts the procedure, potentiating drugs or conditions, or (after sugammadex) displacement of the blocker from its complex can leave or return blockade — hence monitoring until recovery is confirmed.
Toxicity & antidote
Malignant hyperthermia is a pharmacogenetic disorder of skeletal muscle, associated with RYR1 and CACNA1S mutations and triggered by volatile anesthetics and succinylcholine, whose combination raises the risk. Triggering agents produce a change in the muscle cell that raises myoplasmic calcium, which sets off catabolic processes: hypercarbia (a rising end-tidal CO₂ may suggest it), rigidity such as jaw spasm, tachycardia, metabolic acidosis, hyperthermia and rhabdomyolysis, with coagulopathy and renal failure later.
Dantrolene works beyond the neuromuscular junction: it dissociates excitation–contraction coupling, probably by interfering with calcium release from the sarcoplasmic reticulum, and so restores myoplasmic calcium toward normal. Management is to stop all triggering agents, give IV dantrolene and provide supportive care (oxygen and ventilation, hemodynamic support, fluid, electrolyte and acid–base correction).
Succinylcholine’s other emergency is hyperkalemic arrest. In an apparently healthy child who arrests within minutes of the drug — not from ventilation, oxygenation or anesthetic overdose — hyperkalemia is treated immediately, with intravenous calcium, bicarbonate, and glucose with insulin, and malignant hyperthermia is treated at the same time if its signs are present.
Interactions
Contraindications
- No secured airway / inability to ventilate; no concurrent sedation & analgesia — NMBAs cause apnea and paralyze without sedating — using one without ventilation and sedation is catastrophic.
- Personal/family history of malignant hyperthermia (succinylcholine) — In susceptible patients succinylcholine can trigger malignant hyperthermia, and fatal outcomes have been reported.
- Hyperkalemia risk — major burns, crush injury, denervation/spinal cord injury, myopathy (succinylcholine, after ~24–72 h) — Succinylcholine releases potassium; in these states it can cause a lethal hyperkalemic cardiac arrest.
- Known pseudocholinesterase deficiency (succinylcholine) — These patients cannot metabolize succinylcholine and experience dangerously prolonged paralysis.
- Sugammadex with known hypersensitivity to sugammadex or any of its components — Labeled contraindication — reactions have ranged from isolated skin reactions to anaphylaxis and anaphylactic shock, including in patients never exposed before.
- Sugammadex in severe renal impairment, including dialysis use caution — Not recommended by the label — sugammadex is excreted unchanged by the kidney, and safety information is insufficient when clearance is this low.
- Sugammadex to reverse succinylcholine, benzylisoquinolinium blockers (e.g., cisatracurium), or steroidal blockers other than rocuronium and vecuronium use caution — The label says not to use it for these — it reverses only rocuronium and vecuronium.
High-yield
- Phase one fires — succinylcholine depolarizes the end plate (fasciculations) and it cannot repolarize
- Phase two tires — with prolonged exposure the receptors desensitize: train-of-four fade, tachyphylaxis, prolonged weakness
- Neostigmine? — it may prolong phase I; it is considered only for a confirmed phase II block, with an anticholinergic
- Steroids get caged — the aminosteroids rocuronium and vecuronium are the blockers sugammadex encapsulates
- Benzyls break down — cisatracurium, a benzylisoquinolinium, degrades by organ-independent Hofmann elimination and is reversed with neostigmine, not sugammadex
Practice questions
Q1A 35-year-old man with 40% total-body-surface burns is taken back to the operating room on day 10 for grafting. Seconds after IV succinylcholine for intubation he develops peaked T waves and then ventricular fibrillation.
Which mechanism best explains the arrhythmia?
- A.Succinylcholine-induced histamine release
- B.Direct succinylcholine toxicity to the myocardium
- C.Malignant hyperthermia from the burn injury
- D.Accumulation of succinylcholine from reduced plasma cholinesterase
- E.Potassium efflux through upregulated nicotinic receptors after the burn
Show answer
E. Potassium efflux through upregulated nicotinic receptors after the burn — Succinylcholine depolarizes the end plate and lets potassium out of muscle, normally raising serum potassium by up to about 0.5 mEq/L. After the acute phase of a major burn, receptors — including immature ones that are sensitive to succinylcholine — upregulate, the risk peaking at about 7–10 days, so far more potassium is released and fatal arrhythmias can follow; succinylcholine is contraindicated in this setting. Succinylcholine has no direct effect on the myocardium, histamine release is uncommon with normal use, and reduced plasma cholinesterase prolongs paralysis rather than causing hyperkalemia. Malignant hyperthermia is a pharmacogenetic reaction triggered by succinylcholine with volatile anesthetics, not by the burn, and it builds as a hypermetabolic state with hypercarbia, rigidity and fever, whereas this arrest came seconds after the dose with peaked T waves.
Q2A healthy 28-year-old woman receives a single intubating dose of succinylcholine for a 10-minute procedure. Two hours later she still cannot breathe on her own, although her vital signs and temperature are normal.
Which is the most likely explanation?
- A.Development of a phase II block from a single dose
- B.Malignant hyperthermia
- C.Homozygous atypical plasma cholinesterase
- D.Hyperkalemia from succinylcholine-induced potassium release
- E.Accumulation of a hepatic metabolite
Show answer
C. Homozygous atypical plasma cholinesterase — Succinylcholine is ended by plasma cholinesterase, which normally clears a single dose within minutes. About 1 in 2,500 patients is homozygous for the atypical plasma cholinesterase gene and is extremely sensitive, with apnea or prolonged paralysis that is managed with controlled respiration; the dibucaine number helps confirm it. Phase II block follows prolonged exposure rather than one dose, malignant hyperthermia brings hypercarbia, rigidity and fever, and succinylcholine is not cleared by the liver. In a healthy patient the potassium rise (up to about 0.5 mEq/L) is clinically insignificant.
Q3During a 4-hour operation a patient receives a continuous succinylcholine infusion. Near the end, the train-of-four shows four twitches of steadily decreasing strength, increasing amounts of drug have been needed, and spontaneous recovery is slow.
These findings indicate which process?
- A.Phase I depolarizing block
- B.Phase II block, with desensitized receptors
- C.Malignant hyperthermia
- D.Displacement of the blocker from sugammadex
- E.Histamine-mediated hypotension
Show answer
B. Phase II block, with desensitized receptors — With prolonged exposure the depolarizing (phase I) block changes to a phase II block that superficially resembles a nondepolarizing block: the response fades with successive stimuli, tachyphylaxis appears, and paralysis may be prolonged. Phase II is confirmed with a nerve stimulator before any anticholinesterase is considered, and an anticholinergic is given with it to prevent cardiac rhythm disturbances. Malignant hyperthermia would bring hypercarbia, rigidity and fever; sugammadex encapsulates only rocuronium and vecuronium and does not bind succinylcholine; and histamine-mediated flushing and hypotension are uncommon with normal clinical use.
Q4A 70-year-old woman with end-stage kidney disease is paralyzed with cisatracurium for abdominal surgery. At the end of the case, train-of-four monitoring shows four twitches with fade, and the team plans pharmacologic reversal.
Which choice is most appropriate?
- A.Sugammadex alone
- B.Succinylcholine to reset the end plate
- C.Neostigmine alone
- D.Neostigmine together with glycopyrrolate
- E.Dantrolene
Show answer
D. Neostigmine together with glycopyrrolate — Cisatracurium is a benzylisoquinolinium, which sugammadex does not reverse — sugammadex encapsulates only rocuronium and vecuronium. Neostigmine inhibits acetylcholinesterase so acetylcholine outcompetes the blocker; because the extra acetylcholine also stimulates muscarinic receptors and neostigmine has direct cholinomimetic effects, atropine or glycopyrrolate is given before or with it. Cisatracurium was a sound choice here: Hofmann elimination does not depend on the kidney.
Q5Twenty minutes into a laparoscopy under sevoflurane, after intubation with succinylcholine, a 22-year-old man develops jaw rigidity, a rapidly rising end-tidal CO₂, tachycardia and a temperature climbing past 39 °C. His uncle died during anesthesia.
The drug that should be given acts by which mechanism?
- A.Interfering with calcium release from the sarcoplasmic reticulum of skeletal muscle
- B.Blocking nicotinic receptors at the motor end plate
- C.Inhibiting acetylcholinesterase
- D.Encapsulating the neuromuscular blocker in plasma
- E.Blocking muscarinic receptors at the SA node
Show answer
A. Interfering with calcium release from the sarcoplasmic reticulum of skeletal muscle — This is malignant hyperthermia: in susceptible muscle (RYR1 or CACNA1S variants, often familial) volatile anesthetics and succinylcholine raise myoplasmic calcium and drive hypermetabolism. Triggers are stopped and IV dantrolene is given; it acts beyond the neuromuscular junction, probably by interfering with calcium release from the sarcoplasmic reticulum, restoring myoplasmic calcium. A neuromuscular blocker, neostigmine, sugammadex or atropine does not touch the underlying calcium problem.
Sources
- Neuromuscular Blocking Agents — depolarizing vs non-depolarizing, reversal, monitoring — StatPearls (NCBI)
- Succinylcholine Chloride — malignant hyperthermia, hyperkalemia, pediatric boxed warning (FDA label) — FDA / DailyMed
- Depolarizing Neuromuscular Blocking Drugs — mechanism, fasciculations, malignant hyperthermia — StatPearls (NCBI)
- Role of Neuromuscular Blocking Agents in Acute Respiratory Distress Syndrome — updated meta-analysis (Front Pharmacol 2019) — Frontiers (via PMC)
- Quelicin (succinylcholine) — boxed warning, contraindications, malignant hyperthermia (FDA label) — FDA / DailyMed
- Anectine (succinylcholine) — FDA label — FDA / DailyMed
- Rocuronium bromide injection — indications, intubating conditions, train-of-four (FDA label) — FDA / DailyMed
- Vecuronium bromide for injection — FDA label — FDA / DailyMed
- Cisatracurium besylate injection — FDA label — FDA / DailyMed
- Bridion (sugammadex) — reversal of rocuronium/vecuronium (FDA label) — FDA / DailyMed
- Bloxiverz (neostigmine) — reversal of non-depolarizing blockade (FDA label) — FDA / DailyMed
- AHRQ PSNet WebM&M — rocuronium as an ISMP high-alert medication; independent double checks — AHRQ (NCBI Bookshelf)
- Dantrium Intravenous (dantrolene) — malignant hyperthermia crisis (FDA label) — FDA / DailyMed
- Succinylcholine Chloride — hyperkalemia 24–72 h after burns/trauma, myalgia — StatPearls (NCBI)
- WHO INN stem book 2018 — -curium / -curonium — World Health Organization
- Vecuronium bromide for injection (Sun) — FDA label: boxed warning — FDA / DailyMed
- Physiology, Neuromuscular Transmission — endplate potential, nicotinic receptors, acetylcholinesterase — StatPearls (NCBI)
- Neostigmine — reversal timing, paradoxical anticholinesterase weakness — StatPearls (NCBI)
- Neostigmine Methylsulfate Injection — competitive cholinesterase inhibition, anticholinergic co-administration (FDA label) — FDA / DailyMed
- Table of Pharmacogenomic Biomarkers in Drug Labeling (succinylcholine: BCHE; RYR1, CACNA1S) — U.S. Food and Drug Administration
By LearnDrugs
Educational summary for medical students. Always verify against current prescribing information and guidelines. Not medical advice.